Full metadata record

DC Field Value Language
dc.contributor.authorKim, Unyong-
dc.contributor.authorJin, Ming Ji-
dc.contributor.authorLee, Jaeick-
dc.contributor.authorHan, Sang Beom-
dc.contributor.authorIn, Moon Kyo-
dc.contributor.authorYoo, Hye Hyun-
dc.date.accessioned2024-01-20T15:00:54Z-
dc.date.available2024-01-20T15:00:54Z-
dc.date.created2021-09-05-
dc.date.issued2012-05-
dc.identifier.issn0731-7085-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/129281-
dc.description.abstract(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210) is a synthetic cannabinoid, with a classical cannabinoid structure similar to Delta(9)-tetrahydrocannabinol (Delta(9)-THC). In this study, the in vitro metabolism of HU-210 was investigated in human liver microsomes to characterize associated phase I metabolites. HU-210 was incubated with human liver microsomes, and the reaction mixture was analyzed using LC-MS/MS. HU-210 was metabolized in human liver microsomes, yielding about 24 metabolites. These metabolites were structurally characterized on the basis of accurate mass analyses and MS/MS fragmentation patterns. The major metabolic route for HU-210 was oxygenation. Metabolites M1-M7 were identified as mono-oxygenated metabolites; MB-M15, mono-hydroxylated metabolites; M16-M20, di-oxygenated metabolites; and M21-M24, di-hydroxylated metabolites. These results provide evidence for in vivo HU-210 metabolism, and they may be applied to the analysis of HU-210 and its relevant metabolites in biological samples. (C) 2012 Elsevier B.V. All rights reserved.-
dc.languageEnglish-
dc.publisherELSEVIER-
dc.subjectJWH-018-
dc.subjectSYSTEM-
dc.titleTentative identification of phase I metabolites of HU-210, a classical synthetic cannabinoid, by LC-MS/MS-
dc.typeArticle-
dc.identifier.doi10.1016/j.jpba.2012.02.007-
dc.description.journalClass1-
dc.identifier.bibliographicCitationJOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, v.64-65, pp.26 - 34-
dc.citation.titleJOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS-
dc.citation.volume64-65-
dc.citation.startPage26-
dc.citation.endPage34-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000303074800004-
dc.identifier.scopusid2-s2.0-84862784914-
dc.relation.journalWebOfScienceCategoryChemistry, Analytical-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.relation.journalResearchAreaChemistry-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeArticle-
dc.subject.keywordPlusJWH-018-
dc.subject.keywordPlusSYSTEM-
dc.subject.keywordAuthorHU-210-
dc.subject.keywordAuthorSynthetic cannabinoid-
dc.subject.keywordAuthorMetabolism-
dc.subject.keywordAuthorLC-MS/MS-
Appears in Collections:
KIST Article > 2012
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE